Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

Published version of a preprint

Abstract

Abstract Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive. Using a genome-wide loss-of-function screen, we identified that impaired death receptor signaling in ALL led to rapidly progressive disease despite CART19 treatment. This was mediated by an inherent resistance to T-cell cytotoxicity that permitted antigen persistence and was subsequently magnified by the induction of CAR T-cell functional impairment. These findings were validated using samples from two CAR T-cell clinical trials in ALL, where we found that reduced expression of death receptor genes was associated with worse overall survival and reduced T-cell fitness. Our findings suggest that inherent dysregulation of death receptor signaling in ALL directly leads to CAR T-cell failure by impairing T-cell cytotoxicity and promoting progressive CAR T-cell dysfunction. Significance: Resistance to CART19 is a significant barrier to efficacy in the treatment of B-cell malignancies. This work demonstrates that impaired death receptor signaling in tumor cells causes failed CART19 cytotoxicity and drives CART19 dysfunction, identifying a novel mechanism of antigen-independent resistance to CAR therapy. See related commentary by Green and Neelapu, p. 492.

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0813

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 295

Metadata

Authors
Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., Weitzman, M. D., Frey, N. V., Maude, S. L., Grupp, S. A., June, C. H., Gill, S., & Ruella, M.
Affiliations
  • University of Pennsylvania (US)
  • Children's Hospital of Philadelphia (US)
  • Novartis (Switzerland) (CH)
  • 5Novartis Institutes for Biomedical Research, East Hanover, New Jersey.
Corresponding author
  • Singh, Nathan
  • Gill, Saar
  • Ruella, Marco
Venue
Cancer Discovery
Published
2020-04-01
Volume
10
Issue
4
Pages
552-567
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3003403042
Cited by
295
References
49
Citations by year
2026: 28 · 2025: 40 · 2024: 35 · 2023: 55 · 2022: 67 · 2021: 51 · 2020: 18
FWCI
17.25
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship
  • Breakthrough Bike Challenge Buz Cooper Scholarship
  • NCI (K08CA194256, 1K99CA212302, R00CA212302, 1P01CA214278, R01CA226983)
  • American Society of Hematology Scholar Award
  • Mark Foundation ASPIRE award
  • University of Pennsylvania-Novartis Alliance
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
acute lymphoblastic leukemia, CAR T-cell therapy, CD19, chimeric antigen receptor, death receptor signaling, T cell cytotoxicity, CAR T-cell dysfunction, loss-of-function screen, B-cell malignancies, T cell fitness
MeSH terms
Receptors, Chimeric Antigen, Humans, Signal Transduction, Receptors, Death Domain, Precursor Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.